- Home
- INTS vs ESLA Comparison
INTS vs ESLA Comparison
Compare INTS & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- ESLA
- Stock Information
- Founded
- INTS 2012
- ESLA 2021
- Country
- INTS United States
- ESLA United States
- Employees
- INTS N/A
- ESLA N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INTS Health Care
- ESLA Health Care
- Exchange
- INTS Nasdaq
- ESLA Nasdaq
- Market Cap
- INTS 30.8M
- ESLA 32.1M
- IPO Year
- INTS 2023
- ESLA N/A
- Fundamental
- Price
- INTS $0.54
- ESLA $1.03
- Analyst Decision
- INTS Strong Buy
- ESLA Strong Buy
- Analyst Count
- INTS 3
- ESLA 1
- Target Price
- INTS $8.50
- ESLA $16.00
- AVG Volume (30 Days)
- INTS 362.2K
- ESLA 70.6K
- Earning Date
- INTS 05-20-2025
- ESLA 05-20-2025
- Dividend Yield
- INTS N/A
- ESLA N/A
- EPS Growth
- INTS N/A
- ESLA N/A
- EPS
- INTS N/A
- ESLA N/A
- Revenue
- INTS N/A
- ESLA N/A
- Revenue This Year
- INTS N/A
- ESLA N/A
- Revenue Next Year
- INTS N/A
- ESLA N/A
- P/E Ratio
- INTS N/A
- ESLA N/A
- Revenue Growth
- INTS N/A
- ESLA N/A
- 52 Week Low
- INTS $0.50
- ESLA $0.63
- 52 Week High
- INTS $5.28
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- INTS 18.34
- ESLA 50.82
- Support Level
- INTS $0.55
- ESLA $1.02
- Resistance Level
- INTS $0.59
- ESLA $1.22
- Average True Range (ATR)
- INTS 0.12
- ESLA 0.12
- MACD
- INTS -0.02
- ESLA 0.01
- Stochastic Oscillator
- INTS 4.71
- ESLA 47.62
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.